Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HOPE L O'BRIEN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology with Special Qualifications in Child Neurology

NPI
1972704138
CMS profile
647248
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$60,446.42

83 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Biohaven Pharmaceuticals, Inc. $45,791.25 45
BioDelivery Sciences International, Inc. $7,810.26 11
Amgen Inc. $6,236.60 4
AbbVie Inc. $254.20 13
Teva Pharmaceuticals USA, Inc. $155.81 4
SK Life Science, Inc. $114.63 1
Allergan, Inc. $47.07 3
Lilly USA, LLC $36.60 2

Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HOPE L O'BRIEN

NPI 1972704138 · CMS profile ID 647248

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology with Special Qualifications in Child Neurology

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972704138?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HOPE L O'BRIEN, NPI 1972704138, CMS profile ID 647248. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972704138?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). HOPE L O'BRIEN, NPI 1972704138, CMS profile ID 647248. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972704138?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
HOPE L O'BRIEN, NPI 1972704138, CMS profile ID 647248, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1972704138?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

83 matching records · $60,446.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 83 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–83 of 83.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biohaven Pharmaceuticals, Inc. $45.6709/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581103 CMS
Biohaven Pharmaceuticals, Inc. $6.1809/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581097 CMS
Amgen Inc. $19.1009/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825356661 CMS
Allergan, Inc. $11.9908/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792892939 CMS
Biohaven Pharmaceuticals, Inc. $3,000.0008/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581093 CMS
Biohaven Pharmaceuticals, Inc. $125.0008/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581095 CMS
Lilly USA, LLC $17.9008/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818550497 CMS
Biohaven Pharmaceuticals, Inc. $2,000.0008/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581083 CMS
Biohaven Pharmaceuticals, Inc. $33.3308/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581085 CMS
Biohaven Pharmaceuticals, Inc. $3,000.0008/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581087 CMS
Biohaven Pharmaceuticals, Inc. $37.5208/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581089 CMS
Biohaven Pharmaceuticals, Inc. $119.2908/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581091 CMS
AbbVie Inc. $6.9608/09/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795390333 CMS
AbbVie Inc. $6.9608/09/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795390339 CMS
AbbVie Inc. $6.9608/09/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795390343 CMS
Teva Pharmaceuticals USA, Inc. $17.3408/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839502625 CMS
Biohaven Pharmaceuticals, Inc. $3,000.0007/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581079 CMS
Biohaven Pharmaceuticals, Inc. $125.0007/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581081 CMS
AbbVie Inc. $11.1407/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795390327 CMS
Biohaven Pharmaceuticals, Inc. $124.6406/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581077 CMS
Biohaven Pharmaceuticals, Inc. $23.9606/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581075 CMS
Teva Pharmaceuticals USA, Inc. $104.9006/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839502559 CMS
Biohaven Pharmaceuticals, Inc. $50.7906/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581063 CMS
Biohaven Pharmaceuticals, Inc. $51.5606/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581065 CMS
Biohaven Pharmaceuticals, Inc. $66.1806/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581067 CMS
Biohaven Pharmaceuticals, Inc. $495.2006/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581069 CMS
Biohaven Pharmaceuticals, Inc. $365.0006/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581071 CMS
Biohaven Pharmaceuticals, Inc. $145.1206/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581073 CMS
Biohaven Pharmaceuticals, Inc. $100.6406/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581059 CMS
Biohaven Pharmaceuticals, Inc. $39.9406/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581061 CMS
Biohaven Pharmaceuticals, Inc. $2,000.0006/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852581057 CMS
Amgen Inc. $593.7503/31/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825356657 CMS
Amgen Inc. $5,610.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825356653 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,400.00 1
PY2020 $1,214.45 3
PY2021 $60,446.42 83
PY2022 $60,780.34 72
PY2023 $116,597.10 166
PY2024 $166,883.49 152
PY2025 $116,352.40 125

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $161,113.60 86
PY2024 Recipient $11,400.00 3
PY2024 Principal investigator $116,946.76 37
PY2023 Recipient $2,500.78 3
PY2023 Principal investigator $126,205.18 37
PY2022 Recipient $18,393.00 4
PY2022 Principal investigator $56,150.04 11
PY2019 Principal investigator $3,070.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

86 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,440.00 12/31/2025 Non-covered Recipient Entity
HEADACHE CENTER OF HOPE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202534257
Principal investigator 1 Merz Pharmaceuticals, LLC $14,750.00 12/10/2025 Non-covered Recipient Entity
HEADACHE CENTER OF HOPE LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647310
Principal investigator 1 Merz Pharmaceuticals, LLC $2,000.00 12/10/2025 Non-covered Recipient Entity
HEADACHE CENTER OF HOPE LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647314
Principal investigator 1 ABBVIE INC. $299.70 12/04/2025 Non-covered Recipient Entity
HOPE OBRIEN DBA HEADACHE CENTER OF HOPE LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202527500
Principal investigator 1 Merz Pharmaceuticals, LLC $2,000.00 11/14/2025 Non-covered Recipient Entity
HEADACHE CENTER OF HOPE LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647308
Principal investigator 1 Merz Pharmaceuticals, LLC $14,750.00 11/14/2025 Non-covered Recipient Entity
HEADACHE CENTER OF HOPE LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647312
Principal investigator 1 ABBVIE INC. $1,300.00 11/04/2025 Non-covered Recipient Entity
HEADACHE CENTER OF HOPE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202520169
Principal investigator 1 ABBVIE INC. $4,344.84 11/04/2025 Non-covered Recipient Entity
HOPE OBRIEN DBA HEADACHE CENTER OF HOPE LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202521181
Principal investigator 1 Ipsen Innovation $86.80 10/27/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289642
Principal investigator 1 Ipsen Innovation $1,388.10 10/27/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289646
Principal investigator 1 Ipsen Innovation $86.80 10/27/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289694
Principal investigator 1 Ipsen Innovation $2,623.04 10/27/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289700
Principal investigator 1 Ipsen Innovation $978.81 10/27/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289708
Principal investigator 1 Ipsen Innovation $978.81 10/27/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289726
Principal investigator 1 Ipsen Innovation $150.00 10/10/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289638
Principal investigator 1 Ipsen Innovation $1,000.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289634
Principal investigator 1 Ipsen Innovation $86.80 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289636
Principal investigator 1 Ipsen Innovation $86.80 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289640
Principal investigator 1 Ipsen Innovation $500.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289644
Principal investigator 1 Ipsen Innovation $900.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289648
Principal investigator 1 Ipsen Innovation $1,388.10 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289650
Principal investigator 1 Ipsen Innovation $350.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289652
Principal investigator 1 Ipsen Innovation $800.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289654
Principal investigator 1 Ipsen Innovation $86.80 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289656
Principal investigator 1 Ipsen Innovation $978.81 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289658
Principal investigator 1 Ipsen Innovation $3,000.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289660
Principal investigator 1 Ipsen Innovation $100.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289662
Principal investigator 1 Ipsen Innovation $3,393.39 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289664
Principal investigator 1 Ipsen Innovation $63.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289666
Principal investigator 1 Ipsen Innovation $1,550.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289668
Principal investigator 1 Ipsen Innovation $86.80 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289670
Principal investigator 1 Ipsen Innovation $100.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289672
Principal investigator 1 Ipsen Innovation $86.80 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289674
Principal investigator 1 Ipsen Innovation $800.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289676
Principal investigator 1 Ipsen Innovation $2,350.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289678
Principal investigator 1 Ipsen Innovation $3,393.39 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289680
Principal investigator 1 Ipsen Innovation $350.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289682
Principal investigator 1 Ipsen Innovation $1,300.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289684
Principal investigator 1 Ipsen Innovation $50.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289686
Principal investigator 1 Ipsen Innovation $300.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289688
Principal investigator 1 Ipsen Innovation $650.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289690
Principal investigator 1 Ipsen Innovation $978.81 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289692
Principal investigator 1 Ipsen Innovation $3,233.23 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289696
Principal investigator 1 Ipsen Innovation $63.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289698
Principal investigator 1 Ipsen Innovation $86.80 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289702
Principal investigator 1 Ipsen Innovation $3,000.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289704
Principal investigator 1 Ipsen Innovation $1,300.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289706
Principal investigator 1 Ipsen Innovation $350.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289710
Principal investigator 1 Ipsen Innovation $9,100.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289712
Principal investigator 1 Ipsen Innovation $350.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289714
Principal investigator 1 Ipsen Innovation $9,100.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289716
Principal investigator 1 Ipsen Innovation $3,233.23 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289718
Principal investigator 1 Ipsen Innovation $2,350.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289720
Principal investigator 1 Ipsen Innovation $86.80 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289722
Principal investigator 1 Ipsen Innovation $90.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289724
Principal investigator 1 Ipsen Innovation $90.00 10/08/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289728
Principal investigator 1 Eli Lilly and Company $75.00 09/24/2025 Non-covered Recipient Entity
HOPE L. O'BRIEN
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1187881900
Principal investigator 1 ABBVIE INC. $2,897.10 09/03/2025 Non-covered Recipient Entity
HEADACHE CENTER OF HOPE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202508264
Principal investigator 1 Ipsen Innovation $150.00 08/28/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289632
Principal investigator 1 ABBVIE INC. $395.55 08/05/2025 Non-covered Recipient Entity
HEADACHE CENTER OF HOPE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202502098
Principal investigator 1 Ipsen Innovation $150.00 07/31/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289624
Principal investigator 1 Ipsen Innovation $90.00 07/31/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289626
Principal investigator 1 Ipsen Innovation $450.00 07/31/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289628
Principal investigator 1 Ipsen Innovation $450.00 07/22/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289630
Principal investigator 1 Ipsen Innovation $150.00 06/25/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289622
Principal investigator 1 Ipsen Innovation $90.00 06/04/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289616
Principal investigator 1 Ipsen Innovation $150.00 06/04/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289618
Principal investigator 1 Ipsen Innovation $150.00 06/04/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289620
Principal investigator 1 ABBVIE INC. $1,821.15 06/03/2025 Non-covered Recipient Entity
HEADACHE CENTER OF HOPE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202487749
Principal investigator 1 Eli Lilly and Company $28,700.00 05/15/2025 Non-covered Recipient Entity
HOPE L. O'BRIEN
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 1187883414
Principal investigator 1 Ipsen Innovation $482.00 05/15/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289614
Principal investigator 1 Ipsen Innovation $300.00 05/13/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289608
Principal investigator 1 Ipsen Innovation $180.00 05/13/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289610
Principal investigator 1 Ipsen Innovation $300.00 05/13/2025 Non-covered Recipient Entity
Headache Center Of Hope
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289612
Principal investigator 1 ABBVIE INC. $1,595.55 05/06/2025 Non-covered Recipient Entity
HEADACHE CENTER OF HOPE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202481721
Principal investigator 1 Ipsen Innovation $180.00 04/21/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289602
Principal investigator 1 Ipsen Innovation $300.00 04/21/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289604
Principal investigator 1 Ipsen Innovation $300.00 04/21/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289606
Principal investigator 1 ABBVIE INC. $395.55 04/03/2025 Non-covered Recipient Entity
HEADACHE CENTER OF HOPE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202469441
Principal investigator 1 Ipsen Innovation $482.21 03/25/2025 Non-covered Recipient Entity
Headache Center Of Hope
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289600
Principal investigator 1 ABBVIE INC. $2,404.65 03/06/2025 Non-covered Recipient Entity
HEADACHE CENTER OF HOPE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202456280
Principal investigator 1 ABBVIE INC. $395.55 02/05/2025 Non-covered Recipient Entity
HEADACHE CENTER OF HOPE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202444811
Principal investigator 1 Eli Lilly and Company $1,827.55 02/04/2025 Non-covered Recipient Entity
HOPE L. O'BRIEN
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 1187883410
Principal investigator 1 Eli Lilly and Company $10,242.00 01/28/2025 Non-covered Recipient Entity
HOPE L. O'BRIEN
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1187881540
Principal investigator 1 Eli Lilly and Company $974.73 01/27/2025 Non-covered Recipient Entity
HOPE L. O'BRIEN
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1187883412
Principal investigator 1 ABBVIE INC. $695.55 01/02/2025 Non-covered Recipient Entity
HEADACHE CENTER OF HOPE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202436153